Malaysia Hepatitis C drugs market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 – 2030. The market will grow as a result of a number of factors, including the expansion of the pharmaceutical sector, an ageing population, growing healthcare expenditures, urbanisation, better monitoring and screening technologies, and a rise in liver cancer and cirrhosis fatalities brought on by HBV. Some of the major key players in this market are Bristol-Myers Squibb Company Gilead Sciences, Inc. Abbvie Kadmon Holdings Inc. F. Hoffmon La Roche Ltd. GlaxoSmithKline J & J Lupin Pharmaceuticals, Inc. Merck & Co., Inc. Teva Pharmaceuticals and Zydus Pharmaceuticals.
Malaysia HER-2 Negative Breast Cancer Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 – 2030. A number of factors, such as age, obesity, alcoholism, radiation exposure history, family history of breast cancer, family history of the disease, age at first pregnancy, onset of the menstrual cycle, and tobacco use, increase the risk of developing the disease. As a result of lifestyle changes, the incidence and prevalence of breast cancer are rising quickly. All of this will drive a HER-2 Negative Breast Cancer Market.The global HER-2 Negative Breast Cancer market’s major key players are Pfizer, Novartis AG Merck & Co. Inc., GlasxoSmithKline, Eli Lilly and Company, Bristol Myers Squibb Company, AstraZeneca, Lupin, Bayer AG.
Malaysia herceptin biosimilar market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 – 2030. The market grows as a result of increased research and development as well as rising public knowledge of cancer treatments. Additionally, rising healthcare costs and the existence of innovative pipeline products create an opportunity for market expansion. Some of the key players in this market are Mylan N.V., Amgen Inc., Mabion S.A., AryoGen Biopharma, Genor Biopharma, Celltrion Inc., Gedeon Richter Plc, The Instituto Vital Brazil, F. Hoffmann-La Roche AG, and Biocon.
Malaysia homeopathy product market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 – 2030.The market will increase significantly during the forecast period as a result of the ageing and growing paediatric populations. During the forecast period, rising use of homoeopathy as a holistic treatment is anticipated to drive market expansion. Some of the key players in this market are Boiron, Biologische Heilmittel Heel GmbH, A Nelson & Co Ltd, Homeocan, SBL, Hahnemann Laboratories, Medisynth, Ainsworths Ltd., Hevert - Arzneimittel GmbH & Co. KG.
Malaysia Human Insulin Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. An increasing number of people with diabetes, increased exposure to key diabetes risk factors, rising market demand for human insulin analogues, technological advancements in the field of human insulin delivery devices, and favourable medical reimbursements are all expected to lead to an increase in the global market for human insulin. Some of the key players in this market are Sanofi (France), Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Biocon Ltd. (India), Julphar (UAE), Ypsomed AG (Switzerland), BD (U.S.), etc.
Malaysia Human Papillomavirus (HPV) vaccine market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The market for HPV vaccines is mainly being driven by the rising need for prevention of these infections as well as the rising prevalence of human papillomavirus (HPV)-related malignancies of the anus, vulva, vagina, penis, and oropharynx. Some of the key players in this market are Xenetic Biosciences, Inc., Bharat Biotech., AstraZeneca, GlaxoSmithKline plc., Johnson & Johnson, Serum Institute of India Pvt. Ltd, Inovio Pharmaceuticals, Inc, Novartis AG, Sanofi, Merck & Co., Inc.
Malaysia human rotavirus vaccine market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The increasing global supply of goods to comply with and meet the demands of immunisation strategies to eradicate endemic diseases is one of the major reasons boosting market expansion. Globally, there is more government control to ensure that everyone has access to low- or no-cost immunizations. All these factors will drive the growth of human rotavirus vaccine market. Some of the key players in this market are GlaxoSmithKline plc. (UK), Sanofi (France), Pfizer Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Emergent BioSolutions, Inc. (US), CSL Limited (Australia), Inovio Pharmaceuticals, Inc. (US), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan).
Malaysia immune checkpoint inhibitors market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The market for immune checkpoint inhibitors is expanding as a result of factors such as leading an unhealthy lifestyle, a rise in cancer incidence, and genetic mutation and alteration that have an impact on how much the nation's healthcare systems cost. Some of the global key players in this market are AstraZeneca PLC, Eli Lilly and Company (ARMO Biosciences.), Bristol-Myers Squibb Company, Roche Holding AG, Incyte Corporation, Novartis AG, etc.
Malaysia immunosuppressant drugs market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 – 2030. The key factor fueling the growth of the immunosuppressants market is the rise in autoimmune illnesses like multiple sclerosis, alopecia areata, and arthritis. The market growth for immunosuppressants is also influenced by an increase in organ transplant procedures, such as kidney and liver transplants, which is brought on by an increase in the incidence of organ failure. Some of the major key players are Intas Pharmaceuticals Ltd. (Accord Healthcare Ltd.), Mylan N.V., AbbVie Inc., Sanofi S.A., GlaxoSmithKline Plc., Astellas Pharma Inc., Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Pfizer Inc., Novartis International AG (Sandoz), Bristol-Myers Squibb Company.
Malaysia infection control supplies market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The key drivers driving the infection control sector are the expanding number of procedures that call for control measures to stop spreading and the increased prevalence of nosocomial infections. The key players in this market are 3M Company, Belimed AG, Halyard Health, Inc., Getinge Group, Advanced Sterilization Products, Matchana Group, Sterigenics International, MMM Group, Cantel Medical Corporation, STERIS Corporation.
Malaysia infectious wound care management market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The market is expanding as a result of the ageing population, the prevalence of chronic diseases, and technologically advanced and lifestyle-related wound care products. The key players in this market are Smith & Nephew, Mölnlycke Health Care AB, ConvaTec Group PLC, Ethicon (Johnson & Johnson), Baxter International, URGO Medical, Coloplast Corp, Medtronic, 3M, Derma Sciences Inc. (Integra LifeSciences), Medline Industries, Advancis Medical, B. Braun Melsungen AG.
Malaysia Inflammatory Bowel Disease (IBD) drugs market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Numerous variables, including genetic predisposition, environmental triggers, and immune system disturbance, are to blame for the rising prevalence of ulcerative colitis and Crohn's disease. Most people who have ulcerative colitis or Crohn's disease have a family history of the condition. This will act as a driver for Inflammatory Bowel Disease (IBD) drugs market. AbbVie Inc. (U.S.) Takeda Pharmaceutical Company Limited (Tokyo) UCB S.A. (Belgium) Bausch Health Companies Inc. (Canada) Bristol-Myers Squibb Company (U.S.) Pfizer Inc. (U.S.) Celltrion Inc. (South Korea) Johnson & Johnson Services, Inc. (U.S.) are the top key players operating in this market.
Malaysia influenza medications market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Due to factors such an increase in influenza cases and increasing research and development for drug development initiatives, the global market for anti-flu medications is anticipated to rise. As a result of technological developments that generate a significant pipeline of novel pharmaceuticals, this industry may experience growth. Sanofi S.A, Lupin Limited, Teva Pharmaceutical Industries Ltd, Shionogi & Co. Ltd, Macleods Pharmaceutical Ltd, Alvogen Pvt. Ltd, AstraZaneca Plc, BioCryst Pharmaceuticals Inc, F. Hoffman La Roche Ltd, Novartis AG, Vitaris AG. Are the top key players operating in this market.
Malaysia influenza vaccine market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The government's increased emphasis on and support for the influenza vaccination is one of the major factors influencing the global market. Leading market players like CSL Limited, Sanofi, and GlaxoSmithKline plc are increasing their R&D expenditures in order to enhance their production capabilities and concentrate on the introduction of new vaccines, which is what is causing the industry to continue to grow. GlaxoSmithKline plc (U.K.), Sanofi (France), AstraZeneca (U.K.), CSL Limited (Australia), BIKEN Co., Ltd. (Japan), Abbott (U.S.), Sinovac (China) are the top key players operating in this market.
Malaysia inhalation anesthesia market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The market is expected to grow as a result of rising healthcare R&D spending and recent technological and scientific advancements. The market is anticipated to expand because to the rising demand for shorter hospital stays and more accessibility to healthcare services. Halocarbon Products Corporation, Hikima Pharmaceuticals PLC, Lunan Pharmaceutical Group Co. Ltd., Piramal Enterprises Limited, Jiangsu Hengrui Medicine Co. Ltd., Fresenius Kabi AG, AbbVie Inc are the top key players operating in this market.
Malaysia inhaled nitric oxide market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The factors driving the growth of this market are the rising prevalence of respiratory and other associated diseases and ongoing research and development activities. The key players in this market are Mallinckrodt, Linde plc., Air Liquide, BOC Limited, Bellerophon Therapeutics, Beyond Air Inc., Halma plc, VERO Biotech, Nu-Med Plus, Getinge AB, Merck KGaA, Genosys Informatics, Geno, and Perma Pure LLC.
Malaysia interactive wound dressing market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Technology improvements, a growth in the prevalence of chronic wounds, and an increase in surgical procedures are the main factors driving the market for interactive wound dressings. Some of the key players in this market are Johnson & Johnson Medical N.V., Integra LifeSciences Corporation, B. Braun Melsungen AG, Cardinal Health, Medline Industries, Inc., Coloplast Pty Ltd, Medtronic, Beiersdorf AG, Mölnlycke Health Care AB, etc.
Malaysia interferons market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. It is anticipated that the development of novel drug delivery systems and the use of interferons in combination therapy will drive the market for interferons. The key players in this market are Roche, Merck & Co., Bristol-Myers Squibb, Biogen Inc., Bayer AG, Zydus Cadila, Novartis AG, Pfizer Inc., Biosidus, Synairgen, Nanogen, Amega Biotech, Rhein Minapharm Biogenetics.
Malaysia interstitial cystitis drugs market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The rising prevalence of interstitial cystitis and public knowledge of the ailment can be attributed for the market expansion. The key players in this market are Alvogen (CVC Capital Partners), Sandoz International GmbH (Novartis AG), Sun Pharmaceutical Industries Ltd., Accord Healthcare, Avet Pharmaceuticals Inc. (Heritage Pharmaceuticals Inc.), Lannett, Viatris Inc. (Pfizer Inc.), Reckitt Benckiser Group PLC, VistaPharm, Inc, Aurobindo Pharma, Prestige Consumer Healthcare Inc.
Malaysia intravenous solutions market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The rise in the prevalence of malnutrition, the quicker turnaround and higher efficacy associated with intravenous solution therapy, and the rise in the geriatric population all contribute to the growth of the intravenous solutions market. The key players in this market are Fresenius Kabi AG, Pfizer, Inc., Otsuka Pharmaceutical Co., Ltd., Baxter, B. Braun Melsungen AG, Vifor Pharma Management Ltd., JW Life Science, Amanta Healthcare, ICU Medical Inc., Grifols, S.A.
Malaysia irritable bowel syndrome drugs market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Increased illness awareness, the expected timely availability of recently approved drugs, an enhanced payment system, and rising IBS prevalence are the main market drivers for IBS-D pharmaceuticals. The key players in this market are Allergan, Ironwood Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Bausch Health, Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synthetic Biologics, Inc., Astellas Pharma, Inc., and Ardelyx.
Malaysia isoflavones drugs market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The market is primarily driven by three factors: the growing elderly population, technological developments in the production of isoflavones, and the rising prevalence of cancer and other chronic disorders. The major key players in this market are Cargill, BASF, DSM, Shanghai Freemen, and ADM. Other key players include Nexira Inc., Bio-gen Extracts, Sikko Industries, SK Bioland, BioMax, Avestia Pharma, NutraScience Labs, Tradichem S.L., Nutra Green Biotechnology.
Malaysia kidney cancer drugs market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Rising consumer awareness, technical improvements, and the appeal of kidney and renal cancer drugs goods are all contributing reasons to the market's expansion. Some of the major key players in this market are Pfizer Inc (US), AstraZeneca (UK), Bristol-Myers Squibb Company (US), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), etc.
Malaysia knee cartilage repair market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Major factors contributing to the growth of the global knee cartilage repair market include the area's steadily expanding geriatric population, as well as the rising prevalence of different orthopaedic conditions, neuromuscular disorders, sports injuries, and musculoskeletal diseases. The major key players in this market are B. Braun Melsungen AG, Histogenics Corporation, ISTO Biologics, Inc., Johnson & Johnson (DePuy Synthes), MEDIPOST Co., Ltd., Smith & Nephew plc (Osiris Therapeutics, Inc.), Stryker Corporation, Takeda Pharmaceutical Co. Ltd. (TiGenix N.V.), Vericel Corporation, and Zimmer Biomet.
Malaysia lactoferrin market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Technology advances that enable effective operational maintenance, efficient production, an extended product line, elegant design and packaging, and sales monitoring are key growth factors for the lactoferrin industry. The major key players in this market are Hilmar Cheese Company, Pharming Group NV, FrieslandCamina, Synlait Milk Ltd., Ingredia SA, MP Biomedicals, Tatura Milk Industries Ltd., Glanbia plc, APS BioGroup, ProHealth, Fonterra Cooperative Group Ltd., Farbest Brands, InVitria, Milei GmbH, Ferrin-tech LLC.